证券代码：600285 证券简称：羚锐制药 公告编号：2024-051号 河南羚锐制药股份有限公司 关于独立董事公开征集投票权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 征集投票权的起止时间：自2024年12月12日至2024年12月13日（上午 9:30-11:30，下午14:00-16:00） 按照《证券法》《上市公司股东大会规则》《上市公司股权激励管理办法》 《公开征集上市公司股东权利管理暂行规定》《公司章程》等有关规定，河南羚 锐制药股份有限公司（以下简称"公司"）独立董事张钦昱先生受其他独立董事 的委托作为征集人，就公司拟于2024年12月18日召开的2024年第一次临时股东大 会审议的《关于<羚锐制药2024年限制性股票激励计划（草案）>及其摘要的议案》 等相关议案向公司全体股东征集投票权，并提交2024年第一次临时股东大会审议。 一、征集人的基本情况、对表决事项的表决意见及理由 （一）征集人基本信息与持股情况 张钦昱先生为公司第九届董事会独立董事，作为本次征集投票权的征集人， 其 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2024-052号 河南羚锐制药股份有限公司 职工代表大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 河南羚锐制药股份有限公司（以下简称"公司"） 职工代表大会于 2024 年 11 月 28 日在河南新县将军路 666 号会议室召开，就公司拟实施的 2024 年员工 持股计划征求职工代表意见。会议的召开及表决程序符合《公司法》及《公司章 程》的相关规定，经全体与会职工代表民主讨论，形成如下决议： 一、审议通过《关于<羚锐制药 2024 年员工持股计划（草案）>及其摘要的 议案》 公司员工持股计划符合《中华人民共和国公司法》《中华人民共和国证券法》 《关于上市公司实施员工持股计划试点的指导意见》等相关法律、行政法规、规 范性文件和《公司章程》的规定，遵循依法合规、自愿参与、风险自担、资金自 筹的基本原则，在实施员工持股计划前充分征求了公司员工意见，不存在损害公 司及全体股东特别是中小股东利益的情形，亦不存在摊派、强行分配等方式强制 员工参与员工持股计划的 ...

证券简称：羚锐制药 证券代码：600285 河南羚锐制药股份有限公司 2024年员工持股计划 （草案）摘要 二〇二四年十一月 声明 本公司及董事会全体成员保证本次员工持股计划不存在虚假记载、误导性陈述 或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 1 风险提示 一、本次员工持股计划需经公司股东大会批准后方可实施，本次员工持股计划 能否获得公司股东大会批准，存在不确定性。 二、若员工认购金额较低时，本次员工持股计划存在无法成立的风险；若员工 认购资金不足，本次员工持股计划存在低于预计规模的风险。 三、本次员工持股计划设立后将由公司自行管理，本次员工持股计划涉及的具 体资金来源、出资金额、实施方案等为初步结果，能否完成实施，存在不确定性； 本次员工持股计划实施后，公司全部有效的员工持股计划所持有的股票总数 累计不超过公司股本总额的10%，任一持有人持有的员工持股计划份额所对应的 标的股票数量不超过公司股本总额的1%。员工持股计划持有的股票总数不包括员 工在公司首次公开发行股票上市前获得的股份、通过二级市场自行购买的股份及 通过股权激励获得的股份。 四、公司后续将根据规定披露相关进展情况，敬请 ...

北京金台（武汉）律师事务所 关于河南羚锐制药股份有限公司 2024 年限制性股票激励计划 之专项法律意见书 二〇二四年十一月 地址：湖北省武汉市武昌区和平大道三角路恒大首府 55 楼 电话：027-87123860 传真：027-87819960 北京金台(武汉)律师事务所 关于河南羚锐制药股份有限公司 限制性股票激励计划 之专项法律意见书 致：河南羚锐制药股份有限公司 为出具本法律意见书之目的，本所经办律师(以下简称"本所律师")依照现行有 效的法律法规以及中国证券监督管理委员会(以下称"中国证监会")相关规章、规范 性文件的要求和规定，对羚锐制药提供的与本次激励计划事宜有关的法律文件及其他 文件、资料进行了必要的核查和验证。同时，本所律师还审查、验证了本所律师认为 出具本法律意见书所必需核查、验证的其他法律文件及其他文件、资料和证明，并就 有关事项向羚锐制药有关人员进行了询问。 在前述审查、验证、询问过程中，本所律师得到羚锐制药如下承诺及保证：其向 本所律师所提供的文件和所作的陈述和说明是完整、真实和有效的，有关原件及其上 面的签字和印章是真实的，有关副本、复印件等材料与原件一致，且一切足以影响本 法律意 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase of over 15% compared to the CSI 300 index within the next six months [11]. Core Views - The company, Henan Lingrui Pharmaceutical Co., Ltd., has shown a solid performance in the first three quarters of 2024, with a revenue of 2.759 billion yuan, representing a year-on-year growth of 10.07%, and a net profit of 574 million yuan, up 23.10% year-on-year [3][4]. - The company's main revenue and gross profit source is its orthopedic external plaster products, with a gross margin of 75%, which has improved by 0.37 percentage points compared to the same period last year [3][4]. - The report projects earnings per share (EPS) for 2024, 2025, and 2026 to be 1.28 yuan, 1.51 yuan, and 1.75 yuan respectively, with corresponding dynamic price-to-earnings ratios of 16.88, 14.29, and 12.34 [4][6]. Summary by Sections Company Overview - Henan Lingrui Pharmaceutical Co., Ltd. was established in 1988 and has undergone several transformations, including a joint venture in 1992 and a public listing in 2000 [2]. - The largest shareholder is Henan Lingrui Group, holding a 21.48% stake as of the third quarter of 2024 [2]. Financial Performance - For the first three quarters of 2024, the company achieved a net profit of 574 million yuan, with a basic EPS of 1.02 yuan [3]. - The third quarter alone saw a revenue of 853 million yuan, a 5.83% increase year-on-year, and a net profit of 161 million yuan, up 7.8% year-on-year [3]. Profitability Metrics - The gross margin stands at 75%, and the net margin is 20.80%, both showing improvements from the previous year [3]. - The report highlights a decrease in sales and management expense ratios, indicating better cost management [3]. Future Projections - Revenue is expected to grow from 3.808 billion yuan in 2024 to 5.036 billion yuan in 2026, with annual growth rates of approximately 15% [6][9]. - Net profit is projected to increase from 724 million yuan in 2024 to 990 million yuan in 2026, reflecting a robust growth trajectory [6][9].

Investment Rating - The report maintains an "Accumulate" rating for the company [1][5][14] Core Views - The company has shown a slowdown in revenue and profit growth in Q3, attributed to industry disturbances affecting specific products [2][3] - Despite the short-term challenges, the long-term outlook remains positive due to the company's strong brand value and product line, particularly in the orthopedic medication market driven by an aging population [3][5] Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 2.759 billion yuan, a year-on-year increase of 10.07%, and a net profit attributable to shareholders of 574 million yuan, up 23.10% year-on-year [2][3] - Q3 2024 revenue was 853 million yuan, reflecting a year-on-year growth of 5.83%, while net profit for the same period was 161 million yuan, up 7.80% year-on-year [2][3] - The gross margin for Q3 was 72.68%, with a net profit margin of 18.85%, both showing a decline compared to the previous quarter [2] Financial Metrics - The company is projected to achieve revenues of 3.672 billion yuan, 4.153 billion yuan, and 4.660 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 10.9%, 13.1%, and 12.2% [1][5] - Net profit forecasts for the same years are 693 million yuan, 837 million yuan, and 990 million yuan, with growth rates of 22%, 21%, and 18% respectively [1][5] - The report indicates a continuous improvement in financial metrics, with a return on equity (ROE) projected to reach 22.8% in 2024 and 24.1% in 2025 [1][3][8]

证券代码：600285 证券简称：羚锐制药 公告编号：2024-043 号 河南羚锐制药股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 18 日(星期一) 至 11 月 22 日(星期五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600285@lingrui.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2024 年 11 月 25 日(星期一) 下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： （一） 会 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2024-042 号 莫匹罗星软膏由葛兰素史克公司研制，最早于 1988 年在英国获得批准上市， 于 1993 年在我国上市销售，商品名为"百多邦"。莫匹罗星软膏为局部外用抗生 素，适用于革兰阳性球菌引起的皮肤感染，例如：脓疱病、疖肿、毛囊炎等原发 性皮肤感染以及湿疹合并感染、溃疡合并感染、创伤合并感染等继发性皮肤感染。 莫匹罗星软膏为《国家医保目录》乙类产品、《国家基本药物目录》产品。 河南羚锐制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的莫匹罗星软膏《药品注册证书》， 现将相关情况公告如下： 一、药品的基本情况 药品名称：莫匹罗星软膏 剂型：软膏剂 规格：2%（15g：0.3g） 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 上市许可持有人：河南羚锐制药股份有限公司 生产企业：河南羚锐生物药业有限公司 药品批准文号：国药准字 H20249203 药品批准文号有效期：至 2029 年 10 月 28 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的 ...

Investment Rating - The investment rating for the company is "Buy" with a maintained rating [4]. Core Views - The company has shown steady revenue growth, benefiting from the aging population trend, with a reported revenue of 2.75 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 10.1% [1]. - The company is undergoing a second phase of marketing reform, which is expected to enhance its performance elasticity [4]. - The company is a well-known brand in the traditional Chinese medicine patch market, with a diverse product portfolio that supports long-term development [3]. Financial Performance Summary - For Q1-Q3 2024, the company achieved a net profit of 570 million yuan, up 23.1% year-on-year, and a non-recurring net profit of 540 million yuan, up 22.5% year-on-year [1]. - In Q3 2024, the company reported revenue of 850 million yuan, a 5.8% increase year-on-year, with a net profit of 160 million yuan, reflecting a 7.8% year-on-year growth [1]. - The gross profit margin for Q1-Q3 2024 was 75%, an increase of 0.4 percentage points year-on-year, while the sales expense ratio decreased by 1.4 percentage points to 44.4% [2]. Product and Market Positioning - The company has a strong position in the traditional Chinese medicine patch market, with its unique product Tongluo Qutong Gao ranking third in sales among traditional Chinese medicine patches in public hospitals as of H1 2022 [3]. - The company is expanding its product types, including tablets, capsules, and ointments, which enhances its development path and creates synergies with its patch products [3]. - The company is increasing its R&D investment to accelerate the development of new products, focusing on areas such as orthopedic, cardiovascular, and brain health [3]. Earnings Forecast and Valuation - The forecasted net profits for the company are expected to reach 680 million yuan, 800 million yuan, and 930 million yuan for the years 2024, 2025, and 2026, respectively, maintaining previous estimates [4]. - The corresponding price-to-earnings (P/E) ratios are projected to be 18, 15.2, and 13 times for the same years [4].

Summary of Conference Call Company and Industry - The conference call pertains to a pharmaceutical company focusing on various drug products, including oral medications and topical treatments, within the healthcare industry. Key Points and Arguments Market Performance and Sales Strategy - The company has faced challenges in customer traffic and pricing in pharmacies, impacting the promotion of its premium product series. It plans to enhance sales strategies for these products in response to the aging population and the increasing prevalence of joint diseases among younger demographics [1][2] - The sales of fentanyl have shown a growth rate of over 15% in the first three quarters of the year, with expectations for an annual growth of around 20% due to enhanced academic promotion and management of distributors [1][2] - The oral medication segment, particularly the "Peiyuan Tongnao Capsule," has seen a revenue growth of approximately 5% in the first three quarters, with a stronger performance expected in the third quarter due to seasonal increases in cardiovascular diseases [2][3] Product Performance - Other products, including various traditional Chinese medicine formulations, have generated over 100 million yuan in revenue with a growth rate of about 10% year-on-year [3] - The company is focusing on optimizing production efficiency through automation and cost control measures, which include strategic procurement and flexible production planning [4][5] Brand Development and Marketing - The company is committed to building a more influential health brand, with significant investments in brand marketing and community health initiatives across over 300 cities [4][5] - Marketing strategies include leveraging social media to enhance brand awareness and consumer engagement, alongside traditional advertising methods [5] Financial Outlook - The company aims for a revenue growth of 10% to 15% and a net profit growth of over 15% in the coming years, with specific guidance for 2025 to be provided later [5][6] - The company has reported a strong inventory turnover rate of 1.55, attributed to strategic procurement practices [6][7] Challenges and Risks - The company acknowledges external challenges affecting OTC sales growth, with expectations for a gradual recovery in the fourth quarter [11][12] - There are concerns regarding the impact of pricing regulations in certain cities, which may affect sales dynamics [31][32] Future Growth Potential - The company anticipates stable growth for its flagship products, with the "Two Tigers" brand expected to maintain a steady increase in sales, albeit at a slower pace than the growth of the population aged 45 and above [10][12] - The company is exploring new product lines and market opportunities, particularly in the realm of traditional Chinese medicine and OTC products [21][22] Additional Important Information - The company is actively managing its cash flow, with fluctuations noted in the third quarter due to increased accounts receivable and strategic business decisions [26][27] - The company is cautious about future cost increases due to raw material price volatility but remains optimistic about maintaining stable procurement practices [25][30] This summary encapsulates the key insights from the conference call, highlighting the company's strategic focus, market performance, and future outlook within the pharmaceutical industry.